Xenetic Biosciences, Inc. — Q2 2018 Form 10-Q
Reporting period: Three and six months ended June 30, 2018. Xenetic is a development-stage biopharmaceutical company focused on XBIO-101 for progestin-resistant endometrial cancer and its PolyXen technology. The filing reports no revenue from customer contracts or collaboration agreements in the first half of 2018.
Financial performance and liquidity
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $927,069 | $873,837 | $1,633,340 | $2,094,981 |
| General and administrative expense | $1,066,517 | $1,970,471 | $2,188,589 | $3,605,004 |
| Operating loss | $1,993,586 | $2,903,399 | $3,821,929 | $5,759,076 |
| Net loss | $2,026,176 | $2,918,930 | $3,848,694 | $5,784,551 |
| Basic and diluted loss per share | $0.23 | $0.34 | $0.44 | $0.67 |
Margins are not meaningful because the company reported no revenue. Six-month operating cash use was $3,754,941, compared with $1,706,917 in 2017; operating cash use in 2017 was substantially offset by a $3.0 million Shire milestone receipt. Investing cash flow was zero in 2018. Financing provided $1.48 million from warrant exercises. Cash and restricted cash fell by $2,274,941 to $3,324,631.
At June 30, cash was $3,258,121, restricted cash was $66,510, current assets were $4,000,197, and current liabilities were $1,554,092, yielding reported working capital of approximately $2.4 million. Total liabilities were $4,472,610, including a $2,918,518 deferred tax liability. The balance sheet reports no borrowings. Total assets were $17,257,178.
Changes versus prior periods
- Q2 net loss narrowed by 30.6% year over year; first-half net loss narrowed by 33.5%.
- First-half R&D expense fell 22.0%, mainly as development efforts outside XBIO-101 were limited and R&D staffing had been reduced. Q2 R&D expense nevertheless rose 6.1%, reflecting XBIO-101 trial activity and higher share-based expense.
- G&A expense declined 45.9% in Q2 and 39.3% in the first half, largely due to reduced discretionary spending and lower employee-related, professional-services, and investor-relations costs.
- Working capital declined approximately $1.5 million from year-end 2017. Cash declined from $5.53 million at December 31, 2017 to $3.26 million at June 30, 2018, partly offset by warrant exercise proceeds.
Outlook, risks, and other notable items
- Management estimated that available resources would fund planned operations, obligations, and contractual commitments only into Q4 2018. Additional capital or strategic alternatives were needed in the very near term; no financing commitment had been secured. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
- If financing is unavailable, Xenetic may reduce or suspend clinical and preclinical work, cut operating expenses, delay or stop purchasing clinical research services, relinquish asset rights, restructure, or cease operations.
- The Phase 2 XBIO-101 trial began dosing in October 2017, but enrollment and trial progress were slower than expected; management could not predict when preliminary data would be available. The company continued to seek out-licensing arrangements for PolyXen, ErepoXen, and other technologies but could not reliably predict whether or when an agreement would occur.
- Xenetic reported approximately 170 or more patents in its portfolio and described XBIO-101 as its lead investigational candidate. It holds worldwide XBIO-101 rights except in specified CIS countries; the candidate has FDA orphan-drug designation for potential use in progesterone receptor-negative endometrial cancer with progesterone therapy.
- During the first half, 370,000 Class B warrants were exercised for approximately $1.48 million. As of June 30, warrants for 3,152,225 common shares remained outstanding at a weighted-average exercise price of $4.33. Common shares outstanding were 9,403,889 as of August 6, 2018.
- The filing reports no material legal proceedings, no material changes to previously disclosed risk factors, and no material changes in contractual obligations. Management concluded disclosure controls were effective at a reasonable-assurance level.
Key facts for investors to verify
- Whether Xenetic obtained sufficient financing after the filing to address the stated Q4 2018 runway and going-concern uncertainty.
- Subsequent XBIO-101 Phase 2 enrollment, timing of preliminary data, and any changes to the trial plan.
- Any executed licensing, collaboration, or other strategic agreements and the resulting cash proceeds or obligations.
- Current cash burn, working capital, payables, and any equity issuance or warrant exercise that could affect liquidity and dilution.
- Progress on the company’s development programs and whether reduced discretionary spending affects trial execution or other planned activities.